Autopsy report · NCT04691375

A Study of PY314 in Subjects With Advanced Solid Tumors

“Sponsor business decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• Ran for about 2 years 11 months before it stopped.
• 86 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Ikena Oncology

Sponsor type

Industry

Conditions

Advanced Solid Tumor; Gynecologic Cancer; Breast Cancer; Colorectal Cancer; Lung Adenocarcinoma; Renal Cell Carcinoma

Interventions

PY314; Combination Therapy: PY314 + Pembrolizumab

Participants

86

Sites

23

Countries

United States

Trials that died the same way

• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (95% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (94% match in meaning)
• A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)
  “Sponsor decision.” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.